Argenx reports Phase 3 success for Vyvgart Hytrulo in autoimmune myositis, despite subgroup shortfall

Argenx announced that its subcutaneous antibody Vyvgart Hytrulo achieved its primary endpoint in a Phase 3 trial for autoimmune myositis, a rare group of inflammatory muscle diseases.

The trial demonstrated overall efficacy across the studied population, marking a positive step for the drug in this therapeutic area.

The company noted that the drug did not meet the predefined endpoint in a specific patient subgroup, indicating a need for further analysis.